Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults

• Main Authors: Prasad S. Kulkarni (Author), Chandrasekaran Padmapriyadarsini (Author), Johan Vekemans (Author), Ashish Bavdekar (Author), Madhu Gupta (Author), Praveen Kulkarni (Author), B.S. Garg (Author), Nithya J. Gogtay (Author), Muralidhar Tambe (Author), Sanjay Lalwani (Author), Kiranjit Singh (Author), Renuka Munshi (Author), Sushant Meshram (Author), T.S. Selvavinayagam (Author), Krishna Pandey (Author), Devi Madhavi Bhimarasetty (Author), S.R. Ramakrishnan (Author), Chetanraj Bhamare (Author), Abhijeet Dharmadhikari (Author), Chandrashekhar Budhawant (Author), Cyrille J. Bonhomme (Author), Madhuri Thakar (Author), Swarali N. Kurle (Author), Elizabeth J. Kelly (Author), Manish Gautam (Author), Nivedita Gupta (Author), Samiran Panda (Author), Balram Bhargava (Author), Cyrus S. Poonawalla (Author), Umesh Shaligram (Author), Dhananjay Kapse (Author), Bhagwat Gunale (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ABSTRACTAZD1222 (ChAdOx1 nCoV-19) is a replication-deficient adenoviral vectored coronavirus disease-19 (COVID-19) vaccine that is manufactured as SII-ChAdOx1 nCoV-19 by the Serum Institute of India Pvt Ltd following technology transfer from Oxford University/AstraZeneca. The non-inferiority of SII-...